Matthias Therapeutics, LLC
Summary
Matthias Therapeutics, LLC raised $65.0M in an initial Form D filing on 2026-06-01, with Flagship Pioneering and ARCH Venture Partners as related persons. The large raise and top-tier VC involvement signal strong investor confidence in the company's technology venture. The filing is a first notice, with no prior amendments.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Full Analysis
Executive Summary
Matthias Therapeutics, LLC raised $65.0M in an initial Form D filing on 2026-06-01, with Flagship Pioneering and ARCH Venture Partners as related persons. The large raise and top-tier VC involvement signal strong investor confidence in the company's technology venture. The filing is a first notice, with no prior amendments.
Investor Edge
Watch for a D/A amendment within 90 days, which would indicate the company is expanding the round or changing terms. Sophisticated investors should track subsequent SEC filings for any hint of a future IPO or SPAC merger, given the involvement of two top VC firms.
Sector capital positioning
This $65M raise in Technology Venture underscores continued heavy capital flow into deep-tech, high-capital-expenditure startups, likely targeting therapeutics or platform biology. The participation of Flagship and ARCH reinforces their focus on transformative life science bets.
Convergence Signals
No obvious public market convergence signals from this filing alone – no patents, contracts, or legislation mentioned. Monitor for future D/A amendments or public announcements revealing specific technology or partnerships.
Key Takeaways
- $65.0M raised in a single private placement, a significant sum for an initial Form D.
- Flagship Pioneering and ARCH Venture Partners listed as related persons, indicating top-tier VC backing.
- No public ticker or prior amendments; future D/A filings will be key to track capital growth.
Risk Indicators & Flags
No red flags from this initial filing. However, the large amount for a private Tech Venture LLC could imply high burn rate or aggressive valuation. Regulatory concerns: none apparent.
Verification & References
Filing is an initial Form D by Matthias Therapeutics, LLC (SEC CIK 0002104165) filed on 2026-06-02 with first sale 2026-06-01. Accession number 000210416526000003. Verify at SEC EDGAR.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Dare Bioscience, Inc.
Uniform Bio Inc.
DEF 14A - Outlook Therapeutics, Inc.
Anika Therapeutics, Inc.
Strategy Inc
Outlook Therapeutics, Inc.
Pacira BioSciences, Inc.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Declaring a National Emergency to Secure the United States Bulk-Power System
This executive order declares a national emergency to restrict foreign-produced bulk-power system electric equipment that poses national security risks, prohibiting new transactions involving equipment from covered foreign entities and allowing the Secretary of Energy to impose conditions on existing equipment. It directs the Secretary of Energy, in coordination with multiple agencies, to identify, mitigate, and potentially replace risky equipment, and establishes a pre-qualification list for approved vendors.
The National Space Transportation Policy
This memorandum directs multiple agencies to expand and modernize U.S. space launch and reentry infrastructure to support over 1,000 launches annually by 2030, expedite permitting and environmental reviews, develop new federal reentry sites, and strengthen the space transportation industrial base. It mandates range scheduling transparency, spectrum reliability, and workforce development, with specific reports and plans due within 90 to 240 days.
Adjusting Imports of Unmanned Aircraft Systems and Unmanned Aircraft Systems Components into the United States
This proclamation imposes a 100% ad valorem tariff on imports of unmanned aircraft systems (UAS) over 25 kg, those with thermal imagers, docking stations, and certain components, and a 25% tariff on UAS under 25 kg and other components, citing national security under Section 232 of the Trade Expansion Act. It also authorizes the Department of Commerce to establish an onshoring program offering preferential tariff treatment for companies that build new U.S. manufacturing facilities for UAS and components.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →